Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01225276
Other study ID # NGAM-03
Secondary ID
Status Terminated
Phase Phase 2/Phase 3
First received October 6, 2010
Last updated February 20, 2017
Start date October 2011
Est. completion date October 2012

Study information

Verified date February 2017
Source Octapharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

NewGam (current working title for a new IGIV formulation) is a newly developed human normal immunoglobulin solution ready for intravenous administration (IGIV). This study will evaluate the safety and efficacy of three different dosages of NewGam 10% in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy.


Description:

This is a Phase 2/3 study that will take place in 2 stages. The primary objective of Stage 1 (Phase 2 dose-finding part)is to determine and select one dosage from three NewGam maintenance dosage arms in comparison with a placebo arm, based on the percentage of responders (response defined as a decrease, meaning improvement, in the adjusted INCAT disability score by at least 1 point). The selected NewGam dosage and placebo will be employed and compared in Stage 2.

The primary objective of Stage 2 (Phase 3 confirmatory part) is to demonstrate superiority of the maintenance dosage regimen selected at study Stage 1 over placebo in patients with CIDP as assessed by the percentage of responders.

The secondary objective is to evaluate the safety (measured by number of adverse events)and efficacy of NewGam administration in patients with CIDP compared to baseline.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date October 2012
Est. primary completion date October 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients diagnosed as having CIDP based on fulfilment of clinical criteria of the INCAT Group and the definite electrophysiological criteria for CIDP ; patients with MADSAM or pure motor CIDP will be included provided they fulfil these criteria

- Worsening of disability and objective increase in weakness or sensory deficit during the 6 months prior to screening

- >=18 years of age

Exclusion Criteria:

- Unifocal forms of CIDP

- Pure sensory CIDP

- MMN with conduction block

- Treatment of CIDP with immunoglobulins (intravenous or subcutaneous) at any time prior to study entry

- Steroids of any type equivalent to prednisolone or prednisone > 10 mg/day or equivalent plasma exchange (PE) during the last 3 months prior to baseline visit

- Treatment with cyclosporin, methotrexate, mitoxantrone, mycophenolate mofetil, interferon or other immunosuppressive or immunomodulatory drugs during the three months prior to baseline visit

- Clinical evidence of peripheral neuropathy from another

- Known diabetes mellitus

- Other serious medical condition complicating assessment or treatment

- Thromboembolic events: patients with a history of deep vein thrombosis (DVT) within the last year prior to baseline visit or pulmonary embolism ever

- Known IgA deficiency with antibodies to IgA

- History of hypersensitivity, anaphylaxis or severe systemic response to immunoglobulin, blood or plasma derived products, or any component of NewGam

- Known blood hyperviscosity

Study Design


Related Conditions & MeSH terms

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • Polyradiculoneuropathy
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Intervention

Drug:
NewGam 10%
Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam . The maintenance doses to be infused 7 times will be 2.0 g/kg every 21 (+/-4) days.
Placebo
Loading dose at baseline (Week 0) in Placebo arm will be corresponding volume of an authorised 0.9% saline solution . The maintenance doses of the 0.9% saline solution to be infused 7 times will be given every 21 (+/-4) days.
NewGam 10%
Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 1.0 g/kg every 21 (+/-4) days.
NewGam 10%
Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 0.4 g/kg every 21 (+/-4) days.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Octapharma

Outcome

Type Measure Description Time frame Safety issue
Primary Adjusted INCAT disability score Every 3 weeks for 48 weeks (stage 1) or 36 weeks (stage 2)
Secondary Vital Signs During each infusion - Every 3 weeks for 48 weeks (stage 1) or 36 weeks (stage 2)
Secondary Grip Strength Visit 9 & 13
Secondary Nerve Conduction Studies Visti 9 & 13
Secondary Motor Impairment Assessment utlizing the Expanded MRC Sum Score Expanded 'Medical Research Council sum score' will be measured as improvement in MRC units . Every 3 weeks for 48 weeks (stage 1) or 36 weeks (stage 2)
See also
  Status Clinical Trial Phase
Recruiting NCT04356781 - Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT02892890 - Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin N/A
Active, not recruiting NCT03584022 - Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial N/A
Terminated NCT02317562 - Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Phase 3
Recruiting NCT06325878 - Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy N/A
Recruiting NCT06290128 - A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work Phase 3
Completed NCT02293460 - Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Phase 3
Completed NCT02017769 - MRI in Diagnosing and Monitoring CIDP N/A
Withdrawn NCT05257733 - Evaluation of the Diagnostic Contributions of Nerve Ultrasound in Chronic Inflammatory Demyelinating Polyneuropathy Associating Systemic Diseases (CIDP Echo-nerf)
Completed NCT03967899 - Study of Electrical Prognostic Factors of Response to Intravenous Immunoglobulin Treatment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Not yet recruiting NCT04978623 - Role of High Frequency Ultrasound in Demyelinating Polyneuropathies
Active, not recruiting NCT02404298 - Transcriptome Analysis of the Peripheral Blood in CIDP N/A
Completed NCT00099489 - Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Phase 2
Completed NCT01625182 - Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Phase 3
Completed NCT02549170 - A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Phase 3
Completed NCT02955355 - Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Phase 3
Active, not recruiting NCT04658472 - Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Phase 2
Withdrawn NCT04529291 - InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy N/A